Search Bar & Filters
Found 13 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the pharmacokinetics, safety, and immune response of two drugs, RPH-030 and Vectibix4, in patients with metastatic colorectal cancer mCRC who have wild-type RAS genes. The study aims to show that these treatments are equivalent in how the body processes them and to compare their safety and immune effects. Additionally, the study will explore how effective these drugs are when used as first-line therapy combined with FOLFIRI chemotherapy. Participants will receive either RPH-030 or Vectibix4 intravenously at 6 mgkg every two weeks along with FOLFIRI chemotherapy, which includes irinotecan, calcium folinate, and fluorouracil. Treatment starts with FOLFIRI for 8 cycles, then continues with a modified de Gramont regimen. The study includes several periods a screening phase, a main period lasting up to 6 months, a continued therapy period up to 1 year where all patients receive RPH-030, and a treatment extension period lasting up to 2 years for patients with stable disease or response. Follow-up visits occur after treatment ends to monitor survival and disease status. Participants will undergo regular tumor assessments approximately every 6 to 8 weeks, hospitalizations for drug administration at specific visits, and blood sampling for pharmacokinetic and safety evaluations. Researchers will monitor drug levels over time, adverse events, immune reactions, and tumor responses. Follow-up includes imaging or phone calls to track overall survival and disease progression. The total study participation can last up to about 2 years with additional follow-up to ensure thorough monitoring of outcomes and safety.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a new bevacizumab drug made by Mabscale, LLC, compared to Avastin, both combined with paclitaxel and carboplatin, for treating adults with advanced or inoperable non-squamous non-small cell lung cancer NSCLC. This phase III trial aims to show that the new bevacizumab works as well and is as safe as Avastin. The study also looks at how the drug is processed in the body. Participants are randomly assigned to one of two groups. One group receives the Mabscale bevacizumab with paclitaxel and carboplatin, and the other gets Avastin with the same chemotherapy drugs. Treatment cycles last about three weeks, with up to six cycles initially. After that, eligible patients continue with bevacizumab alone every three weeks. The study is double-blind, so neither patients nor researchers know who receives which bevacizumab. During the study, patients will undergo regular assessments including tumor measurements and blood tests. Researchers measure the tumor response at 18 weeks and track progression-free and overall survival at 18 and 42 weeks. The duration of response is also evaluated up to 48 weeks. Safety and side effects are closely monitored throughout the trial, which started in 2023 and will continue until 2027. Participants are followed closely to assess the treatments impact and safety.
Actively Recruiting
Researchers are conducting a multicenter observational study in the Russian Federation focusing on patients with aggressive high-volume metastatic hormone-sensitive prostate cancer mHSPC. The study aims to analyze treatment patterns and evaluate homologous recombination repair mutations HRRm using circulating tumor DNA ctDNA. The population includes those with high-aggressive Gleason score 8-10 and high-volume disease, with known tumor HRRm status determined from routine tumor samples. Approximately 230 patients will be enrolled, equally representing HRRm and wild-type HRR HRRwt groups. This study involves no additional procedures beyond routine clinical practice. Data collection includes two visits the baseline visit gathers demographic, clinical, and treatment history from medical records and patient interviews, as well as blood samples for ctDNA and HRRm testing performed centrally. The final visit occurs at disease progression or after about 12 months to collect follow-up data on progression to metastatic castration-resistant prostate cancer mCRPC and further treatments. Follow-up data may be collected by telephone if the patient cannot visit the study site. Participants contribute data through medical record reviews, interviews, and routine blood sampling. Researchers will monitor various outcomes including treatment types and durations, progression timelines, mutation presence in ctDNA, and clinical characteristics like Gleason scores and metastasis sites. Data will be entered into electronic records, with the study lasting about 36 months until enrollment and follow-up are complete.
Actively Recruiting
Researchers are conducting a national, multicenter, prospective observational study focusing on molecular profiling and first-line treatment approaches for patients with aggressive advanced endometrial cancer stage III-IV in the Russian Federation. The study aims to collect real-world data on the prevalence of specific molecular markers such as POLE mutations, mismatch repair status, p53 abnormalities, HER2, and PD-L1 expression, alongside demographic and clinical characteristics of these patients. The study will include approximately 500 female patients newly diagnosed with aggressive advanced endometrial cancer subtypes who have available biopsy or postoperative archival tumor samples. No additional procedures beyond routine clinical practice will be performed. Molecular testing will be conducted centrally using immunohistochemistry and genetic sequencing techniques on tumor samples. Data collection will occur during two visits the baseline visit to gather demographic, clinical, and treatment information, and a follow-up visit six months later or at disease progression to collect further treatment and progression data. Participants will have their clinical and molecular data entered into electronic records by study physicians. The study will monitor several primary outcomes related to the rates of molecular marker positivity over 24 months and secondary outcomes including chemotherapy use, disease progression, patient demographics, and tumor characteristics over 33 months. The total study duration is expected to be about 27 months or until 500 eligible patients have been enrolled and their data collected, including follow-up.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, how the body processes, and immune response to BCD-236 combined with chemotherapy in women with relapsed or metastatic triple negative breast cancer TNBC who have received previous treatments. This is a Phase 2 study that compares BCD-236 plus chemotherapy versus chemotherapy alone in patients whose cancer has returned or progressed after earlier therapies. Participants will be randomly assigned to one of two groups one receiving BCD-236 by intravenous infusion plus chemotherapy chosen by the investigator, and the other receiving chemotherapy alone. Treatment continues until the cancer worsens, side effects become intolerable, or the study ends. During the study, participants will undergo regular assessments including tumor measurements and health evaluations to monitor response and side effects. The main outcome measured is the overall response rate at 24 weeks, with secondary outcomes including progression-free survival, overall survival, disease control rate, time to response, and duration of response assessed at various times up to 102 weeks. Participants will be monitored closely throughout their treatment and follow-up periods.
Actively Recruiting
Researchers are studying adult patients with Neurofibromatosis type 1 NF1 in Russia to evaluate clinical and patient-reported outcomes in routine care settings. This observational, open-label, single-arm, multi-center cohort study focuses on adults diagnosed with NF1 and associated plexiform neurofibromas PN. Participants are adults aged 18 years or older with confirmed NF1 and PN diagnosis verified by clinical assessment, ultrasound imaging, MRI, or biopsy. The study includes patients with existing PN-associated symptoms who are either newly diagnosed or have PN without prior MEK-inhibitor therapy. No investigational drugs are given, as this is a non-interventional study observing routine care. During the study, participants provide data at their initial visit, including demographics, clinical history, PN characteristics, comorbidities, disability degree, and prior examinations. Researchers collect information on hospitalizations and disease progression over time. The primary outcomes include age at inclusion and diagnosis, body measurements, symptom duration, and disability changes. Participants are followed according to routine care until study completion in 2028.
Actively Recruiting
Researchers are evaluating the efficacy and safety of cariprazine in treating schizophrenia among adolescents aged 13 to 17 years. This international, multicenter study is designed as a randomized, double-blind, placebo-controlled trial to understand how cariprazine affects symptoms of schizophrenia in this younger population. Participants will be randomly assigned to receive either cariprazine capsules at doses of 1.5 mg or 4.5 mg once daily, or matching placebo capsules once daily. The treatment phase lasts for six weeks, during which participants take the assigned capsules orally every day. During the study, participants will be monitored regularly to assess changes in their schizophrenia symptoms using the Positive and Negative Syndrome Scale PANSS. Researchers will also evaluate safety and tolerability throughout the trial. The main measurement is the change in PANSS total score from the start to the end of the six-week period. The study is designed to last until December 2026.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the effects and mechanisms of Mexidol both injectable solution and oral tablets in patients experiencing the hyperacute and acute stages of ischemic stroke. This pilot, randomized, multicenter, open-label study aims to understand how Mexidol impacts clinical outcomes and brain imaging results compared to Glycine tablets, with 100 stroke patients and 20 healthy volunteers enrolled. The study focuses on safety and efficacy during early stroke treatment phases. The trial includes two patient groups one receives Mexidol solution intravenously twice daily for 10 days followed by Mexidol FORTE tablets three times daily for 60 days, alongside standard stroke care. The other group receives Glycine sublingual tablets once daily for 5 days with standard care. Healthy volunteers do not receive treatment but provide baseline biomarker data. Treatments are given according to current clinical guidelines. Participants undergo multiple evaluations including brain imaging MRI and CT, blood tests for biomarkers and coagulation, and clinical assessments like the National Institutes of Health Stroke Scale and modified Rankin Scale. Assessments occur at baseline, day 11, and follow-ups up to day 90. Safety and tolerability are monitored throughout the study, which spans from initial treatment to three months post-treatment.
Actively Recruiting
Researchers are evaluating the effectiveness of adjuvant ribociclib combined with hormone therapy using aromatase inhibitors with or without GnRH agonists in patients with hormone receptor-positive HR HER2-negative stage II-III breast cancer. This observational study includes two groups a prospective cohort receiving ribociclib plus aromatase inhibitors, and a retrospective cohort treated with aromatase inhibitor monotherapy. The study aims to analyze outcomes based on tumor grade, lymph node involvement, and hormone therapy response in real-world clinical practice in Russia. Participants in the prospective group receive ribociclib along with aromatase inhibitors GnRH agonists, while the retrospective group includes patients treated with aromatase inhibitor monotherapy. Data collection includes both primary prospective data and secondary retrospective data from medical records. The study does not involve experimental treatment assignments but observes existing treatment patterns and outcomes. Participants will be monitored over several years with assessments at months 36, 48, and 60 to evaluate invasive breast cancer-free survival and other related outcomes. Quality of life questionnaires and safety data including adverse events are collected at multiple time points up to 60 months. The study involves continuous data review to assess treatment adherence, disease recurrence, and patient well-being throughout the observation period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of adding REAMBERIN4 meglumin sodium succinate, a 1.5% infusion solution, to standard rehydration therapy for patients with diabetic ketoacidosis DKA. The study is a combined, two-stage, multicenter, randomized, double-blind phase IIIII trial designed to determine the best dose of REAMBERIN4 and compare it with a placebo to see if it helps resolve DKA more quickly and allows patients to leave the intensive care unit and hospital sooner. Participants will receive either REAMBERIN4 infusion at doses of 750 ml or 1500 ml per day or a placebo infusion of 0.9% normal saline at the same volume. The infusion will continue for up to 2 days or until the diabetic ketoacidosis resolves, whichever happens first. The study has two stages stage 1 tests two doses of the medication to find the optimal dose, and stage 2 recruits more patients to compare this optimal dose with placebo in equal groups. During the study, researchers will monitor the time from starting therapy to the resolution of diabetic ketoacidosis within 48 hours. Participants will undergo assessments to confirm their DKA status and safety monitoring throughout the infusion period. The study includes adults aged 18 to 75 years with confirmed DKA and diabetes. The total participation duration varies depending on the resolution of DKA, and safety follow-up will be conducted until hospital discharge.
1-10 of 13
1